LAIYANG, China, Feb. 12 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) (''Genesis'' or the ''Company''), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:00 a.m. Eastern on Tuesday, February 17, 2009 to discuss financial results for the second quarter ended December 31, 2008 of its fiscal year 2009.
The conference call will include Mr. Wubo Cao, Chairman and CEO, Mr. Haibo Xu, COO, and Ms. Elsa Sung, CFO, of Genesis Pharmaceuticals.
To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 419-5570. International callers should call (617) 896-9871. The Conference Passcode is 694 125 61. If you are unable to participate in the call at that time, replay of the conference call will be available from Tuesday, February 17 at 11:00 a.m. Eastern until Tuesday, March 3, 2009. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Replay Passcode is 398 758 52.
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule and granule form. The Company maintains a representative office in the U.S. For more information, refer to http://www.genesispharmaceuticals.com .
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact: Genesis Pharmaceuticals Enterprises, Inc. Ms. Elsa Sung, CFO Tel: +1-954-727-8435 Email: email@example.com Web: http://www.genesispharmaceuticals.com CCG Investor Relations, Inc. Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: firstname.lastname@example.org Web: http://www.ccgir.com
|SOURCE Genesis Pharmaceuticals Enterprises, Inc.|
Copyright©2009 PR Newswire.
All rights reserved